Overall aim: To investigate mechanisms for individual variability in drug response and to establish principles for personalized dosing in selected pharmacotherapies, currently those related to immunosuppression, chemotherapy, anti-infectives and statins.
This may be achieved by:
- The combination of pharmacokinetics (PK), pharmacodynamics (PD) and pharmacogenomics (PGx), sources for individual variability in the response of specific drugs.
- The identification of variant genotypes or altered gene expression affecting drug response. Biomarkers for the above.
- Models for decision support, including population PK/PD models and integrative models for biomarkers.
Current projects (and collaborations)
- Belatacept in kidney transplantation (Erasmus MC, Rotterdam)
- Tacrolimus new PK/PD principles for individualization (Dept of Transplant Medicine)
- MarkIT pilot study on biomarkers for tacrolimus and mycophenolate in renal transplant recipients (Dept of Transplant Medicine)
- Pharmacogenetic panels; High throughput screening (Dept of Genetics)
- Pediatric and adult hemato-oncology and transplantation, e.g. busulfan, glucocorticoids, tacrolimus (Dept of Pediatrics; Dept of Hematology)
- Immunosuppressants and pancreatic islets (Institute of Surgical Research, UiO)
- Personalized statin treatment (Dept of Medicine, Drammen Hospital)